According to a new report by Polaris Market Research, the U.S. biomarkers market was valued at USD 25.92 billion in 2024 and is projected to reach USD 106.03 billion by 2034, expanding at a CAGR of 15.16% over the forecast period. Growth is underpinned by rising cancer incidence, growing chronic disease burden, and robust government support for precision-medicine research and development.

What Is Driving U.S. Biomarkers Market Growth?

Demand is climbing as rising cancer and chronic disease incidence converges with a supportive federal regulatory framework. Healthcare providers and pharmaceutical companies are prioritizing precision diagnostics, pushing biomarker adoption across oncology, cardiology, and neurology. Polaris analysts note that the National Cancer Institute's estimate of approximately 2,041,910 new U.S. cancer cases in 2025 positions the segment for sustained double-digit growth through 2034, with efficacy biomarkers emerging as the largest revenue contributor and validation biomarkers posting the fastest incremental gains.

Key Trends Shaping the U.S. Biomarkers Industry

Precision Medicine Initiatives Broaden Clinical Adoption

Government programs such as the Precision Medicine Initiative and the FDA's Fit-for-Purpose Initiative are integrating biomarkers into national healthcare strategy, weaving personalized treatment planning into routine care and strengthening the regulatory landscape for emerging drug development tools.

Next-Generation Sequencing Drives Technology Advancement

Falling sequencing costs and expanding genomic databases are accelerating adoption of next-generation sequencing for detailed disease profiling, particularly in oncology, rare diseases, and pharmacogenomics, supporting a broader technology advancement trend across clinical workflows.

AI-Powered Analytics Reshape the Competitive Landscape

Companies are intensifying investment in AI-powered analytics, liquid biopsy technologies, and companion diagnostics, reflecting a competitive landscape shift toward real-time, individualized therapeutic approaches and disease-specific biomarker panels.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/us-biomarkers-market

Market Segmentation: Breaking Down the U.S. Biomarkers Market

Polaris segments the U.S. biomarkers market by type, research area, technology, disease indication, and application, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

Efficacy biomarkers are the largest segment, projected to grow at a robust pace through 2034 as pharmaceutical companies increasingly use them to evaluate drug response and guide clinical trial design. Validation biomarkers are projected to grow at the fastest pace, driven by the need for reproducible, standardized data that meets rigorous regulatory requirements.

By Research Area

Genomics dominated the market in 2024, supported by widespread use in identifying genetic predispositions and tailoring therapies in oncology and rare diseases. Proteomics is expected to exhibit the fastest growth rate as mass spectrometry and protein microarray technologies deepen insight into complex disease mechanisms such as Alzheimer's and autoimmune disorders.

By Technology and Disease Indication

Immunoassays accounted for a substantial share in 2024, valued for high sensitivity and cost-effectiveness in point-of-care diagnostics, while next-generation sequencing is projected to witness the fastest growth as its diagnostic potential becomes more broadly recognized. Among disease indications, cancer dominated the market in 2024 given the reliance on biomarker-guided therapy selection, while neurological disorders are projected to expand at the fastest CAGR, reflecting the more than 7 million Americans currently living with Alzheimer's disease, according to the Alzheimer's Association.

By Application

Clinical diagnostics accounted for significant share in 2024 as biomarker-based tests become standard for early detection and risk assessment, while personalized medicine is expected to witness the fastest growth as targeted therapy protocols expand and companion diagnostics portfolios grow.

As a country-specific report, Polaris's U.S. biomarkers coverage centers on national-level demand drivers rather than a cross-country regional breakdown, with healthcare spending and R&D infrastructure serving as the primary growth levers. The Centers for Medicare & Medicaid Services reported that U.S. healthcare spending rose 7.5% in 2023, totaling USD 4.9 trillion — a scale of investment that continues to underpin the country's biomarker research and clinical infrastructure.

Competitive Landscape: Leading U.S. Biomarkers Companies

Key players profiled in the report include Abbott Laboratories, Illumina, Inc., Thermo Fisher Scientific, Inc., Quest Diagnostics Incorporated, and Guardant Health, Inc., who are focusing on new assay development, digital integration, and strategic collaborations with academic institutions to strengthen market position across the genomics and clinical diagnostics segments outlined above. Recent moves include Columbia University's June 2025 launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics and the University of Houston's USD 3 million CPRIT-backed cancer immunotherapy biomarker core facility announced in May 2025.

Why It Matters for Buyers Evaluating the U.S. Biomarkers Market

For stakeholders researching the U.S. biomarkers market, this report benchmarks market share, segment-level pricing, and forecast data — by type, research area, technology, disease indication, and application — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing diagnostics suppliers, investors sizing entry points, and strategy teams tracking personalized medicine as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Sports Nutrition Market

Waste to Energy Market

Carob Powder Market

Behind the Wheel: Role of Sensors in Modern Automobiles

Cellular Modem Market

Cellular Modem Market

Sandarac Market

Oleochemicals Market

Cashew Nutshell Liquid Market